Source: Virtual Congress 2021 – Clinical evolution, management and outcomes of patients with rare diffuse parenchymal lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Šterclová (Praha, Czech Republic), M. Doubkova (Brno, Czech Republic), R. Kralova (Pardubice, Czech Republic), P. Pohunek (Prague, Czech Republic), V. Bartos (Hradec Kralove, Czech Republic), V. Lostakova (Olomouc, Czech Republic), P. Musilova (Jihlava, Czech Republic), M. Vasakova (Prague, Czech Republic). Definition of progressive fibrosing interstitial lung diseases and approach to the patientPosition paper of Czech Respiratory Society. 2378

Member's Comments

No comment yet.

Related content which might interest you: Report on the registration of interstitial lung diseases in Spain Source: Eur Respir J 2003; 22: Suppl. 45, 198s Year: 2003 Case presentation: Should we always treat IgG4-related lung disease? Source: International Congress 2014 – Biomarkers of asthma and clinical immunology Year: 2014 Clinical study of pediatric interstitial lung diseases in China Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Combined pulmonary fibrosis and emphysema: A report from the Hellenic Interstitial Lung Diseases group Source: Annual Congress 2010 - Different patterns of interstitial lung disease Year: 2010 B-lymphocyte targeted therapy for patients with progressive fibrosing mediastinitis Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014 Development of the interstitial lung disease multidiciplinary team meeting 2005-2013 Source: International Congress 2015 – Kaleidoscope of nursing research Year: 2015 Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019 Year: 2019 Aetiological panorama in the diagnosis of interstitial lung diseases Source: International Congress 2014 – ILDs 5 Year: 2014 Clinical highlights from the 2011 ERS Congress in Amsterdam Source: Eur Respir J 2012; 39: 1501-1510 Year: 2012 Respiratory medicine meets rheumatology: What is new in connective tissue diseases – ILD Source: ERS webinar 2021: Respiratory medicine meets rheumatology: What is new in connective tissue diseases – ILD Year: 2021 Prevalence and incidence of interstitial lung diseases (ILDs) in a French multi-ethnic county Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Paediatric interstitial lung disease Source: ERS Course 2016 Year: 2016 Paediatric interstitial lung disease Source: Eur Respir Mon; 2009: 46: 319–354 Year: 2009 Effects of limb training in symptomatic patients with interstitial lung disease of different severity and etiology: A pilot study Source: International Congress 2014 – Best posters in pulmonary rehabilitation 2 Year: 2014 Desquamative interstitial pneumonia in a Danish cohort, treatment response and outcome Source: International Congress 2014 – ILDs 2 Year: 2014 Genetics of fibrosing lung diseases Source: Eur Respir J 2005; 25: 915-927 Year: 2005 6MWT performance by means of Spiropalm in patients affected by fibrotic idiopathic interstitial pneumonias: Preliminary observations Source: International Congress 2014 – ILDs 6 Year: 2014 Epidemiology of interstitial lung diseases. The RENIA study Source: Eur Respir J 2001; 18: Suppl. 33, 440s Year: 2001 Establishment of the consecutive registration system for pulmonary alveolar proteinosis in Japan: Updated incidence, prevalence and surveillance for intractable cases Source: International Congress 2016 – Orphan diseases I Year: 2016